Yahoo
NasdaqCM - Delayed Quote USD

Silexion Therapeutics Corp (SLXN)

0.2599 -0.0191 (-6.85%)
At close: October 2 at 4:00:01 PM EDT
0.2550 -0.0049 (-1.89%)
After hours: October 2 at 7:59:26 PM EDT
Chart Range Bar
Loading chart for SLXN
  • Previous Close 0.2790
  • Open 0.2665
  • Bid 0.2002 x 200
  • Ask 0.3243 x 200
  • Day's Range 0.2599 - 0.2990
  • 52 Week Range 0.2360 - 42.0000
  • Volume 1,959,616
  • Avg. Volume 9,945,196
  • Market Cap (intraday) 1.445M
  • Beta (5Y Monthly) -0.36
  • PE Ratio (TTM) --
  • EPS (TTM) -18.6000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.00

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

silexion.com

13

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SLXN
98.65%
S&P 500 (^GSPC)
12.81%

1-Year Return

SLXN
99.31%
S&P 500 (^GSPC)
15.00%

3-Year Return

SLXN
99.98%
S&P 500 (^GSPC)
80.08%

5-Year Return

SLXN
99.98%
S&P 500 (^GSPC)
77.25%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -3.55M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-4M
-3M
-2M
-1M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
5.00 Average
0.2599 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 12/15/2025
Analyst Litchfield Hills
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 6

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    1.76M

  • Enterprise Value

    -43.07k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    40.02

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -13.96M

  • Diluted EPS (ttm)

    -18.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.23M

  • Total Debt/Equity (mrq)

    3,204.54%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.2599 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: